![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. 5-acetamido-n-(2- Hydroxyethyl)-2,4,6-triiodoisophthalamic Acid
2. Agelix
3. Ioxitalamic Acid, Sodium Salt
4. Ioxithalamate
5. Sodium Ioxithalamate
6. Telebrix
7. Telebrix 38
8. Vasobrix
1. 28179-44-4
2. Acido Ioxitalamico
3. Acide Ioxitalamique
4. Acidum Ioxitalamicum
5. Iooxitalamic Acid
6. Ag 58107
7. Ioxithalamic Acid
8. 3-acetamido-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoic Acid
9. Telebrix
10. 3-acetamido-5-((2-hydroxyethyl)carbamoyl)-2,4,6-triiodobenzoic Acid
11. Ioxitalamic Acid Sodium Salt
12. 967rdi7z6k
13. Chebi:83517
14. Ag-58107
15. Ioxitalamic Acid (inn)
16. 3-(acetamido)-5-[[(2-hydroxyethyl)amino]carbonyl]-2,4,6-triiodo-benzoic Acid
17. Ioxitalamic Acid [inn]
18. Vasobrix
19. 5-acetamido-n-(2-hydroxyethyl)-2,4,6-triiodoisophthalamic Acid
20. 3-(acetylamino)-5-[[(2-hydroxyethyl)amino]carbonyl]-2,4,6-triiodobenzoic Acid
21. 3-(acetylamino)-5-{[(2-hydroxyethyl)amino]carbonyl}-2,4,6-triiodobenzoic Acid
22. Acido Iossitalamico
23. Acidum Joxitalamicum
24. Ioxitalamic Acid [inn:dcf]
25. Ioxitalamicacid
26. Acido Iossitalamico [dcit]
27. Unii-967rdi7z6k
28. 3-(acetylamino)-5-(((2-hydroxyethyl)amino)carbonyl)-2,4,6-triiodobenzoic Acid
29. Acide Ioxitalamique [inn-french]
30. Acido Ioxitalamico [inn-spanish]
31. Acidum Ioxitalamicum [inn-latin]
32. Einecs 248-887-5
33. Mls006010884
34. Schembl455411
35. Acido Ioxitalamico;ioxitalamate
36. Chembl2107239
37. Dtxsid60182457
38. Ioxitalamic Acid [mart.]
39. Ioxitalamic Acid [who-dd]
40. Act03777
41. Amy24792
42. Bcp34384
43. Zinc4216615
44. Mfcd00867942
45. Sodium 3-acetamido-5-(2-hydroxyethylcarbamoyl)-2,4,6-triiodobenzoate
46. Db13444
47. Smr004701800
48. Ft-0659353
49. D07418
50. F20665
51. 179i444
52. Sr-01000945067
53. Q3604532
54. Sr-01000945067-1
55. W-110718
56. 5-acetamido-2,4,6-triiodo-n-(2-hydroxyethyl)-isophthalamic Acid
57. 3-(acetylamino)-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic Acid
58. 3-acetamido-2,4,6-triiodo-(n-beta-hydroxyethyl)isophthalic Acid Monoamide
Molecular Weight | 643.94 g/mol |
---|---|
Molecular Formula | C12H11I3N2O5 |
XLogP3 | 1.2 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 5 |
Exact Mass | 643.7802 g/mol |
Monoisotopic Mass | 643.7802 g/mol |
Topological Polar Surface Area | 116 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 451 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Ioxitalamate in both of its available forms is indicated for exploration of the digestive tract by tomodensitometry or by regular gastroduodenal radiography. Its use is restrained to the cases in which the administration of barium sulfate is not recommended or contraindicated. The intravascular administration of ioxitalamate is contraindicated as it may present significant side effects.
Ioxitalamate presents a very large osmolality which is related to the presence of renal toxicity, vasodilatation, bradycardia and pulmonary hypertension. This large osmolality allows ioxitalamate to move slowly in the bowel allowing for analysis for later follow excretion in the feces.
Contrast Media
Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)
V08AA05
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
V - Various
V08 - Contrast media
V08A - X-ray contrast media, iodinated
V08AA - Watersoluble, nephrotropic, high osmolar x-ray contrast media
V08AA05 - Ioxitalamic acid
Absorption
When administered ioxitalamate is not absorbed in the GI tract. In the case of presence of an intestinal perforation, ioxitalamate is completely absorbed. When administered intravascularly, ioxitalamate is rapidly distributed in the interstitial space and intravascular compartment.
Route of Elimination
As ioxitalamate is not absorbed in the normal intestine, the elimination route of this compound is entirely performed by the feces. When absorbed due to the presence of an intestinal perforation, ioxitalamate presents a rapid renal elimination. when ioxitalamate is administered intravascularly, it is eliminated unchanged mainly via renal excretion through glomerular filtration without reabsorption or tubular secretion. In the cases of renal failure, the elimination is mainly performed in the biliary, salivary, sudoral and colic route.
Volume of Distribution
The volume of distribution of ioxitalamate is 194 ml/kg.
Clearance
The total clearance rate of ioxitalamate is 120 ml/min.
The rapid clearance suggests that ioxitalamate is not metabolized in the body.
The elimination half-life of ioxitalamate is 1.1 hours.
Ioxitalamate acts as a bowel opacifier which facilitates the interpretation of the anatomy and differentiation of bowel loops from soft tissue masses.